Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Schmidt KJ et al. | Letter: short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - authors' reply. | 2013 | Aliment. Pharmacol. Ther. | pmid:23336691 |
Yamamoto T et al. | Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study. | 2016 | Aliment. Pharmacol. Ther. | pmid:26762838 |
Travis S | Review article: saving the colon in severe colitis - the case for medical therapy. | 2006 | Aliment. Pharmacol. Ther. | pmid:16961749 |
McSharry K et al. | Systematic review: the role of tacrolimus in the management of Crohn's disease. | 2011 | Aliment. Pharmacol. Ther. | pmid:21999607 |
Itoh S et al. | Inhibition of CN (protein phosphatase-2B) suppresses Ca2+-mediated acid secretion in rats. | 2002 | Aliment. Pharmacol. Ther. | pmid:11966520 |
Herrlinger KR et al. | Infliximab as rescue medication for patients with severe ulcerative/indeterminate colitis refractory to tacrolimus. | 2010 | Aliment. Pharmacol. Ther. | pmid:20175769 |
Högenauer C et al. | Effect of oral tacrolimus (FK 506) on steroid-refractory moderate/severe ulcerative colitis. | 2003 | Aliment. Pharmacol. Ther. | pmid:12940927 |
Yamamoto T et al. | Letter: which patient profile for tacrolimus in ulcerative colitis? Authors' reply. | 2016 | Aliment. Pharmacol. Ther. | pmid:27137731 |
Laharie D and Poullenot F | Letter: which patient profile for tacrolimus in ulcerative colitis? | 2016 | Aliment. Pharmacol. Ther. | pmid:27137730 |
Haagsma EB et al. | Inflammatory bowel disease after liver transplantation: the effect of different immunosuppressive regimens. | 2003 | Aliment. Pharmacol. Ther. | pmid:12848624 |